The BLA also requests BAT2506 be declared interchangeable with Simponi. Bio-Thera and Intas entered into a license and commercialization agreement for BAT2506 in February 2025.

Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, today announced that the U.S. Food and Drug ...

The BLA also requests BAT2506 be declared interchangeable with Simponi. Bio-Thera and Intas entered into a license and commercialization agreement for BAT2506 in February 2025.

The BLA also requests BAT2506 be declared interchangeable with Simponi. Bio-Thera and Intas entered into a license and commercialization agreement for BAT2506 in February 2025.

The best shoes for Peloton and home exercise bikes are tried and tested by our in-house Tom's Guide fitness team, including models by Peloton, Rapha and more.

Explore the rise and market race of anti-IL23p19 therapies in Inflammatory Bowel Disease (IBD), specifically Ulcerative Colitis (UC). Stay informed on the latest advancements and treatment options.

The U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) for BAT2506, a proposed biosimilar to Simponi (golimumab). The FDA goal date set under the Biosimilar ...

GUANGZHOU, China I July 16, 2025 I Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, today announced ...